72|139|Public
5|$|Adderall is {{available}} as immediate-release tablets or two different extended-release formulations. The extended-release capsules are generally {{used in the}} morning. A shorter, 12-hour extended-release formulation {{is available}} under the brand Adderall XR and {{is designed to provide}} a therapeutic effect and plasma concentrations identical to taking two doses 4hours apart. The longer extended-release formulation, approved for 16 hours, is available under the brand Mydayis. In the United States, the immediate and extended release (XR) formulations of Adderall are both available as generic drugs, while Mydayis is available only as a <b>brand-name</b> <b>drug.</b>|$|E
25|$|Ondansetron (marketed {{under the}} brand name Zofran) was {{developed}} in the mid-1980s by GlaxoSmithKline in London. It was granted US patent protection in September 1987, received a use patent June 1988, and was approved by the US FDA in January 1991. It was granted another divisional patent in November 1996. Finally, owing to GlaxoSmithKline's research on pediatric use, ondansetron's patent protection was extended until December 2006. By this final year of its patent (2006), Zofran had become the 20th highest-selling <b>brand-name</b> <b>drug</b> in the United States, with sales of US$1.3 billion in the first 9 months of 2006 (80% from the US). The first generic versions were approved by the US FDA in December 2006, with marketing approval granted to Teva Pharmaceuticals USA and SICOR Pharmaceuticals.|$|E
2500|$|Before {{a company}} can market a generic drug, it needs to file an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration, seeking to {{demonstrate}} therapeutic equivalence to a previously approved [...] "reference-listed drug" [...] and proving that it can manufacture the drug safely and consistently. [...] For an ANDA to be approved, the FDA requires the bioequivalence of a generic drug to be between 80% and 125% of the innovator product. (This range {{is part of a}} statistical calculation, and does not mean that generic drugs are allowed to differ from their brand-name counterparts by up to 25 percent.) The FDA evaluated 2,070 studies conducted between 1996 and 2007 that compared the absorption of brand-name and generic drugs into a person’s body. The average difference in absorption between the generic and the <b>brand-name</b> <b>drug</b> was 3.5 percent, comparable to the difference between two batches of a <b>brand-name</b> <b>drug.</b> [...] Non-innovator versions of biologic drugs, or biosimilars, require clinical trials for immunogenicity in addition to tests establishing bioequivalency. These products cannot be entirely identical because of batch-to-batch variability and their biological nature, and they are subject to extra rules.|$|E
30|$|Introduction: Use {{of generic}} drugs, which are bioequivalent to <b>brand-name</b> <b>drugs,</b> {{is now a}} common practice. However, there is still concern among {{patients}} and physicians that <b>brand-name</b> <b>drugs</b> are more efficient than generic drugs (1).|$|R
40|$|Generic drug {{utilization}} {{has risen}} dramatically, from 19 % of scrips in 1984 to 47 % in 2001, thus bringing significant direct dollar savings. Generic drug use may also yield indirect savings if it lowers {{the average price}} of those <b>brand-name</b> <b>drugs</b> that are still purchased. Prior work indicates - and we confirm - that generic competition does not induce brand-name producers to lower prices. However, consumer choices between generic and <b>brand-name</b> <b>drugs</b> could affect {{the average price of}} those <b>brand-name</b> <b>drugs</b> that are purchased. We use nationally representative panel data on drug utilization and costs for the years 1996 - 2001 to examine how the share of an individual's prescriptions filled by generics affects his average out-of-pocket cost for <b>brand-name</b> <b>drugs.</b> Our principal finding is that a higher generic scrip share lowers average brand-name prices to consumers, presumably because consumers are more likely to substitute generics when the price gap is great. This effect is substantial: a 10 % increase in the consumer's generic scrip share is associated with a 15. 6 % decline in the average price he pays for <b>brand-name</b> <b>drugs.</b> ...|$|R
25|$|Providing a 50% {{discount}} on <b>brand-name</b> <b>drugs</b> for Medicare patients beginning in 2011. By 2020, {{the government would}} pay to provide up to 75% {{discount on}} <b>brand-name</b> and generic <b>drugs,</b> eventually closing the coverage gap.|$|R
5000|$|Upcoding: {{inflating}} a charge, for example, {{a doctor}} prescribes a generic drug, but the bill lists a costlier, <b>brand-name</b> <b>drug</b> ...|$|E
5000|$|He is {{also the}} Chair of the Alliance for Patient Access, which, {{according}} to the Wall Street Journal [...] "represents physicians and is largely funded by the pharmaceutical industry. The contributors mostly include <b>brand-name</b> <b>drug</b> makers and biotechs, but some - such as Pfizer and Amgen - are also developing biosimilars." ...|$|E
5000|$|Initially {{known as}} CS-514, {{pravastatin}} is a derivative of ML236B (compactin), which was identified in a fungus called Penicillium citrinum in the 1970s by researchers of the Sankyo Pharma Inc. [...] It is being marketed outside Japan by the pharmaceutical company Bristol-Myers Squibb. In 2005, Pravachol was the 22nd-highest selling <b>brand-name</b> <b>drug</b> in the United States, with sales totaling $1.3 billion.|$|E
40|$|Pharmaceutical {{expenditures}} {{have grown}} rapidly in recent decades, and now total nearly 10 % {{of health care}} costs. Generic drug utilization has risen substantially alongside, from 19 % of scripts in 1984 to 47 % in 2001, thus tempering expenditure growth through significant direct dollar savings. However, generic drugs may lead to indirect savings as well if their use reduces {{the average price of}} those <b>brand-name</b> <b>drugs</b> that are still purchased. Prior work indicates that brand-name producers do not lower their prices in the face of generic competition, and our study confirms that finding. However, prior work is silent on how the mix of consumer choices between generic and <b>brand-name</b> <b>drugs</b> might affect the average price of those <b>brand-name</b> <b>drugs</b> that are purchased. We use a nationally representative panel of data on drug utilization and costs for the years 1996 - 2001 to examine how the share of an individual’s prescriptions filled by generics (generic script share) affects his average out-of-pocket cost for <b>brand-name</b> <b>drugs,</b> and the net cost paid by the insurer. Our principal finding is that a higher generic script share lowers average brand-name prices to consumers, presumably because consumers are more likely to substitute generics when <b>brand-name</b> <b>drugs</b> would cost them more. This effect is substantial: a 10 % increase in the consumer’s generic script share is associated with a 15. 6 % decline in the average price paid for <b>brand-name</b> <b>drugs</b> by consumers. This implies that the potential cost savings to consumers from generic substitution are far greater than prior work suggests. In contrast, the percentage reduction in average brand costs to health plans is far smaller, and statistically insignificant. JEL Classification Codes I 11; D 40...|$|R
40|$|This {{research}} was supported with an unrestricted educational grant from the Merck Company Foundation, the philanthropic arm of Merck & Co., Inc. Pharmaceutical expenditures have grown rapidly in recent decades, and now total nearly 10 % of health care costs. Generic drug utilization has risen substantially alongside, from 19 % of scrips in 1984 to 47 % in 2001, thus tempering expenditure growth through significant direct dollar savings. However, generic drugs may lead to indirect savings as well if their use reduces {{the average price of}} those <b>brand-name</b> <b>drugs</b> that are still purchased. Prior work indicates that brand-name producers do not lower their prices in the face of generic competition, and our study confirms that finding. However, prior work is silent on how the mix of consumer choices between generic and <b>brand-name</b> <b>drugs</b> might affect the average price of those <b>brand-name</b> <b>drugs</b> that are purchased. We use a nationally representative panel of data on drug utilization and costs for the years 1996 - 2001 to examine how the share of an individual’s prescriptions filled by generics (generic scrip share) affects his average out-of-pocket cost for <b>brand-name</b> <b>drugs,</b> and the net cost paid by the insurer. Our principal finding is that a higher generic scrip share lowers average brand-name prices to consumers, presumably because consumers are more likely to substitute generics when <b>brand-name</b> <b>drugs</b> would cost them more. This effect is substantial: a 10 % increase in the consumer’s generic scrip share is associated with a 15. 6 % decline in the average price paid for <b>brand-name</b> <b>drugs</b> by consumers. This implies that the potential cost savings to consumers from generic substitution are far greater than prior work suggests. In contrast, the percentage reduction in average brand costs to health plans is far smaller, and statistically insignificant...|$|R
50|$|Generally, not all {{drugs are}} covered {{at the same}} out of pocket cost to the beneficiary. This gives {{participants}} incentives to choose certain drugs over others. This is most often implemented—as {{is the case for}} drug coverage for those not on Medicare—through incentives to use generic <b>drugs</b> over <b>brand-name</b> <b>drugs.</b> The incentive is also often implemented via a system of tiered formularies in which some <b>brand-name</b> <b>drugs</b> are less expensive than others and not subject to step therapy.|$|R
5000|$|Patient {{advocacy}} groups that lobby for payment for specialty drugs include the Alliance for Patient Access (AfPA), formed in 2006 and {{which according to}} a 2014 article in the Wall Street Journal [...] "represents physicians and is largely funded by the pharmaceutical industry. The contributors mostly include <b>brand-name</b> <b>drug</b> makers and biotechs, but some—such as Pfizer and Amgen—are also developing biosimilars." ...|$|E
5000|$|Before {{a company}} can market a generic drug, it needs to file an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration, seeking to {{demonstrate}} therapeutic equivalence to a previously approved [...] "reference-listed drug" [...] and proving that it can manufacture the drug safely and consistently. [...] For an ANDA to be approved, the FDA requires the bioequivalence of a generic drug to be between 80% and 125% of the innovator product. (This range {{is part of a}} statistical calculation, and does not mean that generic drugs are allowed to differ from their brand-name counterparts by up to 25 percent.) The FDA evaluated 2,070 studies conducted between 1996 and 2007 that compared the absorption of brand-name and generic drugs into a person’s body. The average difference in absorption between the generic and the <b>brand-name</b> <b>drug</b> was 3.5 percent, comparable to the difference between two batches of a <b>brand-name</b> <b>drug.</b> [...] Non-innovator versions of biologic drugs, or biosimilars, require clinical trials for immunogenicity in addition to tests establishing bioequivalency. These products cannot be entirely identical because of batch-to-batch variability and their biological nature, and they are subject to extra rules.|$|E
5000|$|Respondent Solvay Pharmaceuticals filed a New Drug Applicationb in 1999 and {{received}} a patent in 2003 for its <b>brand-name</b> <b>drug,</b> Androgel, used for treating low testosterone levels in men. Two generic-drug companies, Actavis and Paddock filed patents for generic drugs that were modeled after Androgel later that year. Solvay then sued Actavis for patent infringement under [...] "paragraph IV" [...] litigation, but the FDA eventually approved Actavis's generic drug for the market after the dispute over the validity of Solvay's patent had continued for three years.|$|E
5000|$|Create a new {{pharmaceutical}} {{agency to}} purchase drugs in bulk, negotiate prices with drug companies and find less costly options to <b>brand-name</b> <b>drugs.</b>|$|R
50|$|In the US, where {{a system}} of private {{healthcare}} is in place, a formulary {{is a list of}} prescription drugs available to enrollees, and a tiered formulary provide financial incentives for patients to select lower-cost drugs. For example, under a 3-tier formulary, the first tier typically includes generic drugs with the lowest cost sharing (e.g., 10% coinsurance), the second includes preferred <b>brand-name</b> <b>drugs</b> with higher cost sharing (e.g., 25%), and the third includes non-preferred <b>brand-name</b> <b>drugs</b> with the highest cost-sharing (e.g., 40%).|$|R
40|$|In {{the context}} of a three-stage model with {{consumers}} differing in their health insurance coverage, the paper shows that there exist conditions under which the price of <b>brand-name</b> <b>drugs</b> increases following the entry of generic <b>drugs.</b> <b>Brand-name</b> pricing Generic entry Generic competition paradox Health insurance...|$|R
50|$|The act {{extended}} the patent exclusivity terms of new drugs, and importantly tied those extensions, in part, {{to the length}} of the FDA approval process for each individual drug. For generic manufacturers, the Act created a new approval mechanism, the Abbreviated New Drug Application (ANDA), in which the generic drug manufacturer need only demonstrate that their generic formulation has the same active ingredient, route of administration, dosage form, strength, and pharmacokinetic properties ("bioequivalence") as the corresponding <b>brand-name</b> <b>drug.</b> This act has been credited with essentially creating the modern generic drug industry.|$|E
50|$|Because {{submitting}} an NDA {{is expensive}} and lengthy, the Congress {{set out to}} create an easier path for generic drugs to be issued to the public. Congress passed the Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act. Under Hatch-Waxman a generic drug may be approved for use without the onerous provisions of an NDA provided the generic drug is identical to an already approved <b>brand-name</b> <b>drug.</b> Under Hatch-Waxman the generic drug manufacturer is prohibited from making any changes in the drug or from making any changes to the already approved label.|$|E
5000|$|Leibowitz {{was active}} in {{preserving}} competition {{in the health care}} and pharmaceutical sectors. He criticized of “pay-for-delay” settlements in the pharmaceutical industry.The Commission aggressively worked at stopping pay-for-delay patent settlements in the pharmaceutical industry. These are deals in which a <b>brand-name</b> <b>drug</b> firm pays its potential generic drug into the market. [...] As Leibowitz explained, the practice results not only in windfalls for both companies—sometimes of more than a billion dollars—but also in higher drug prices for consumers. Leibowitz has published articles on this issue and advocates bringing cases against firms that engage in these practices.|$|E
40|$|A {{letter report}} {{issued by the}} Government Accountability Office with an {{abstract}} that begins "When GAO compared prices paid by the Department of Defense (DOD) and the Department of Veterans Affairs (VA) for a sample of 83 drugs purchased in the first calendar quarter of 2012, DOD's average unit price {{for the entire sample}} was 31. 8 percent ($ 0. 11 per unit) higher than VA's average price, and DOD's average unit price for the subset of 40 generic drugs was 66. 6 percent ($ 0. 04 per unit) higher than VA's average price. However, VA's average unit price for the subset of 43 <b>brand-name</b> <b>drugs</b> was 136. 9 percent ($ 1. 01 per unit) higher than DOD's average price. These results were consistent with each agency obtaining better prices on the type of drugs that made up the majority of its utilization: generic drugs accounted for 83 percent of VA's utilization of the sample <b>drugs</b> and <b>brand-name</b> <b>drugs</b> accounted for 54 percent of DOD's utilization of the sample drugs. DOD officials told GAO that in certain circumstances they are able to obtain competitive prices for <b>brand-name</b> <b>drugs</b> [...] even below the prices for generic equivalents [...] and therefore will often preferentially purchase <b>brand-name</b> <b>drugs.</b> ...|$|R
25|$|<b>Brand-name</b> <b>drugs</b> may be swapped for generics; {{if this is}} {{not wanted}} by the doctor, they may write {{dispense}} as written in the local language on the prescription.|$|R
40|$|A {{letter report}} {{issued by the}} Government Accountability Office with an {{abstract}} that begins "The growing cost of <b>brand-name</b> prescription <b>drugs</b> [...] FDA-approved drug products that typically have patent protection [...] is a concern for patients, payers, and providers of health care [...] particularly when price increases are large and occur suddenly. A 2008 congressional hearing by the Joint Economic Committee drew attention to some small market prescription drugs that had an extraordinary price increase [...] a price increase of 100 percent or more at a single point in time. GAO was asked to examine extraordinary price increases for <b>brand-name</b> prescription <b>drugs.</b> Specifically, GAO examined the: (1) frequency of extraordinary price increases for <b>brand-name</b> prescription <b>drugs</b> from 2000 to 2008, (2) characteristics of the <b>brand-name</b> prescription <b>drugs</b> that had extraordinary price increases, and (3) factors {{that contributed to the}} extraordinary price increases experienced by these <b>brand-name</b> prescription <b>drugs.</b> To determine the frequency and characteristics of the <b>brand-name</b> prescription <b>drugs</b> that experienced an extraordinary price increase, GAO reviewed drug pricing and other data from a pharmaceutical industry compendium. To illustrate the factors that may contribute to extraordinary price increases, GAO developed case studies of six <b>brand-name</b> prescription <b>drugs</b> identified from the analysis of drug pricing data. These <b>brand-name</b> prescription <b>drugs</b> were selected based on factors including price, and the percentage and number of price increases. ...|$|R
5000|$|Under the [...] "paragraph IV route" [...] of the Hatch-Waxman Act, {{a generic}} drug {{manufacturer}} can assure the U.S. Food and Drug Commission (FDA) {{that it would}} not infringe upon the patent of a <b>brand-name</b> <b>drug</b> by proving that the patent was invalid or that the sale of the generic drugs will not violate the brand-name's patent. This would constitute a challenge to the patent, and usually lead to litigation between the brand-name and generic manufacturers. The FDA then must withhold approving the generic drugs for a 30-month period while the courts resolve the dispute. If the dispute does not resolve within that period, the FDA could then approve the generic for the market.|$|E
50|$|Ondansetron (marketed {{under the}} brand name Zofran) was {{developed}} in the mid-1980s by GlaxoSmithKline in London. It was granted US patent protection in September 1987, received a use patent June 1988, and was approved by the US FDA in January 1991. It was granted another divisional patent in November 1996. Finally, owing to GlaxoSmithKline's research on pediatric use, ondansetron's patent protection was extended until December 2006. By this final year of its patent (2006), Zofran had become the 20th highest-selling <b>brand-name</b> <b>drug</b> in the United States, with sales of US$1.3 billion in the first 9 months of 2006 (80% from the US). The first generic versions were approved by the US FDA in December 2006, with marketing approval granted to Teva Pharmaceuticals USA and SICOR Pharmaceuticals.|$|E
5000|$|In October 2014, the Federal Court of Canada {{released}} {{decisions on}} Section 8 of the Patented Medicines (Notice of Compliance) Regulations {{as it relates}} to litigation between Sanofi-Aventis and Apotex (Sanofi-Aventis et al. v. Apotex Inc.). Section 8 explains how a <b>brand-name</b> <b>drug</b> manufacturer may be liable to a generic drug manufacturer for damages caused by a generic drug's delay in reaching market, caused as a result of unsuccessful prohibition proceedings {{on the part of the}} brand-name manufacturer. [...] Sanofi argued that the current framework for quantifying damages in a hypothetical market inherently leads to a windfall for the generic manufacturer. In October 2014, the Federal Court of Canada affirmed that section 8 of the Regulations was constitutionally and jurisdictionally valid, a decision which Sanofi appealed.|$|E
40|$|Health {{insurance}} companies curb price-insensitive {{behavior and the}} moral hazard of insureds by means of cost-sharing, such as tiered co-payments or reference pricing in drug markets. This paper evaluates the effect of price limits –below which drugs are exempt from co-payments– on prices and on demand. First, using a difference-in-differences estimation strategy, {{we find that the}} new policy decreases prices by 5 percent for generics and increases prices by 4 percent for <b>brand-name</b> <b>drugs</b> in the German reference price market. Second, estimating a nested-logit demand model, we show that consumers appreciate co-payment exempt drugs and calculate lower price elasticities for <b>brand-name</b> <b>drugs</b> than for generics. This explains the different price responses of <b>brand-name</b> and generic <b>drugs</b> and shows that price-related co-payment tiers are an effective tool to steer demand to low-priced drugs...|$|R
50|$|In 2013, the {{coverage}} gap starts at $2,970. Drug manufacturers pay 50 percent on covered <b>brand-name</b> <b>drugs,</b> {{but the entire}} cost of the drug is counted towards the amount needed {{to get out of}} {{the coverage}} gap which is $4,750.|$|R
50|$|Using {{bioequivalence}} as {{the basis}} for approving generic copies of drug products was established by the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act. This Act expedites the availability of less costly generic drugs by permitting FDA to approve applications to market generic versions of <b>brand-name</b> <b>drugs</b> without conducting costly and duplicative clinical trials. At the same time, the brand-name companies can apply for up to five additional years longer patent protection for the new medicines they developed to make up for time lost while their products were going through FDA's approval process. <b>Brand-name</b> <b>drugs</b> are subject to the same bioequivalence tests as generics upon reformulation.|$|R
5000|$|These reforms had {{the effect}} of {{increasing}} the time, and the difficulty, required to bring a drug to market. [...] One of the most important statutes in establishing the modern American pharmaceutical market was the 1984 Drug Price Competition and Patent Term Restoration Act, more commonly known as the [...] "Hatch-Waxman Act" [...] after its chief sponsors. The act extended the patent exclusivity terms of new drugs, and tied those extensions, in part, to the length of the FDA approval process for each individual drug. For generic manufacturers, the Act created a new approval mechanism, the Abbreviated New Drug Application (ANDA), in which the generic drug manufacturer need only demonstrate that their generic formulation has the same active ingredient, route of administration, dosage form, strength, and pharmacokinetic properties ("bioequivalence") as the corresponding <b>brand-name</b> <b>drug.</b> This act has been credited with in essence creating the modern generic drug industry.|$|E
40|$|Preliminary Version This paper {{analyzes}} {{the impact of}} a negotiated scheme and a generic reference price system in comparison to a simple copayment system in a vertical di¤erentiation model with switching costs. The duopolistic market structure with an o¤-patent <b>brand-name</b> <b>drug</b> competing in a Stackelberg-mode with a generic version is adopted from Merino-Castéllo 2003. <b>Brand-name</b> <b>drug</b> and generic version di¤er in perceived quality. This framework is extended by a …rst-mover advantage due to switching costs as speci…ed by Schmalensee 1982 : Pre-purchase-uncertainty concerning the generics’quality results in a reduced willingness to pay and thus forces the imitator to o¤er a discount to attract consumers, whereas uncertainty no longer applies to the o¤-patent <b>brand-name</b> <b>drug</b> in the duopolistic period considered here. Switching costs are of fundamental importance in pharmaceutical markets and provide an explanation for observations of the so-called "generic paradoxon". Consequently, two opposed e¤ects on the <b>brand-name</b> <b>drug</b> can be observed: Whereas price regulation-whether due to a reference price system a negotiated scheme- leads to a disadvantage for the <b>brand-name</b> <b>drug,</b> uncertainty regarding the properties of the generics results in an competitive advantage for the <b>brand-name</b> <b>drug...</b>|$|E
40|$|This paper {{analyzes}} {{a maximum}} price {{system and a}} reference price system in a vertical differentiation model with a <b>brand-name</b> <b>drug</b> and a generic. In particular, both instruments are compared {{with respect to their}} performance in reducing public expenditure, limiting financial exposure of patients, improving access to pharmaceuticals, and stimulating competition. For identical regulatory prices, free pricing under the reference system tends to result in a higher price for the <b>brand-name</b> <b>drug.</b> For identical price reductions of the <b>brand-name</b> <b>drug,</b> the lower reimbursement amount under the reference price system results in lower health expenditure, but higher financial exposure of patients. Total welfare is higher under the maximum price system...|$|E
5000|$|Apotex {{is known}} for {{actively}} fighting patent protections on <b>brand-name</b> <b>drugs,</b> primarily through litigation means. A New York Times cover piece on Apotex's founder, Bernard Sherman, described Sherman's work to get new generic drugs to market as [...] "something of a crusade." [...] The article goes {{on to explain that}} while some generic drug manufacturers cut deals with <b>brand-name</b> manufacturers over <b>drug</b> patents, Bernard Sherman and Apotex are against such deal-making.|$|R
50|$|The Snyders {{played a}} major role in {{establishing}} the standards and approval process with the U.S. Food and Drug Administration for generic pharmaceuticals. In 1991, Snyder expressed his concerns regarding FDA approval processes that had multiple chemists raising issues regarding generic versions of <b>brand-name</b> <b>drugs.</b>|$|R
40|$|The article {{discusses}} {{the factors that}} influence the efficacy and safety of generic drugs, including regular generics, biosimilars, and generic nonbiological complex drugs. It emphasizes the importance of adequate regulatory requirements to provide a comparable therapeutic efficacy and a comparable cost-effectiveness ratio for generics versus <b>brand-name</b> <b>drugs.</b> </p...|$|R
